Compare Fate Therapeutics vs Immunomic Therapeutics
Customers evaluate the quality of Fate Therapeutics's products using the following success metrics.
Overview
Fate Therapeutics is 17 yrs old and is based in United States.
Fate Therapeutics (NASDAQ: FATE) is a biotechnology company developing stem cell modulators (SCMs), biologic or small molecule compounds that guide cell fate, to treat patients with very few therapeutic options. Fate Therapeutics' lead clinical program, ProHema, consists of pharmacologicallyenhanced hematopoietic stem cells (HSCs) designed to improve HSC support during the normal course of a stem cell transplant for the treatment of patients with hematologic malignancies. The Company is also advancing a pipeline of human recombinant proteins, each with mechanisms of action, for skeletal muscle, beta-Aislet cell, and post-Aischemic tissue regeneration. Fate Therapeutics also applies its induced pluripotent stem cell (iPSC) technology to offer a highly efficient platform to recapitulate human physiology for commercial scale drug discovery and therapeutic use.
Immunomic Therapeutics is 19 yrs old and is based in United States.
Immunomic Therapeutics operates as a development-stage biotechnology company focusing on the Universal Intracellular Targeted Expression (UNITE) nucleic acid immunotherapy platform. The company develops lysosomal-associated membrane protein-based vaccines for the treatment of allergies and other human health targets. It was founded in 2005 and is based in Rockville, Maryland.
Demo Video
Leadership
Sheng Ding (Founder)
William G Hearl (Founder, Chief Executive Officer, President)
Funding
Investors
Polaris Partners, ARCH Venture Partners
HLB, Paycheck Protection Program
Product
Benefits
Products
Customers
Known Partners
Why They Buy
Information not available because Fate Therapeutics has not claimed their profile.
Work for Fate Therapeutics? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Fate Therapeutics?
Claim your profile now.
Information not available because Immunomic Therapeutics has not claimed their profile.
Work for Immunomic Therapeutics? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Immunomic Therapeutics?
Claim your profile now.